Cargando…
Genetic platelet depletion is superior in platelet transfusion compared to current models
Genetically modified mice have advanced our knowledge on platelets in hemostasis and beyond tremendously. However, mouse models harbor certain limitations, including availability of platelet specific transgenic strains, and off-target effects on other cell types. Transfusion of genetically modified...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271594/ https://www.ncbi.nlm.nih.gov/pubmed/31537686 http://dx.doi.org/10.3324/haematol.2019.222448 |
_version_ | 1783542119777959936 |
---|---|
author | Salzmann, Manuel Schrottmaier, Waltraud C. Kral-Pointner, Julia B. Mussbacher, Marion Volz, Julia Hoesel, Bastian Moser, Bernhard Bleichert, Sonja Morava, Susanne Nieswandt, Bernhard Schmid, Johannes A. Assinger, Alice |
author_facet | Salzmann, Manuel Schrottmaier, Waltraud C. Kral-Pointner, Julia B. Mussbacher, Marion Volz, Julia Hoesel, Bastian Moser, Bernhard Bleichert, Sonja Morava, Susanne Nieswandt, Bernhard Schmid, Johannes A. Assinger, Alice |
author_sort | Salzmann, Manuel |
collection | PubMed |
description | Genetically modified mice have advanced our knowledge on platelets in hemostasis and beyond tremendously. However, mouse models harbor certain limitations, including availability of platelet specific transgenic strains, and off-target effects on other cell types. Transfusion of genetically modified platelets into thrombocytopenic mice circumvents these problems. Additionally, ex vivo treatment of platelets prior to transfusion eliminates putative side effects on other cell types. Thrombocytopenia is commonly induced by administration of anti-platelet antibodies, which opsonize platelets to cause rapid clearance. However, antibodies do not differentiate between endogenous or exogenous platelets, impeding transfusion efficacy. In contrast, genetic depletion with the inducible diphtheria toxin receptor (iDTR) system induces thrombocytopenia via megakaryocyte ablation without direct effects on circulating platelets. We compared the iDTR system with antibody-based depletion methods regarding their utility in platelet transfusion experiments, outlining advantages and disadvantages of both approaches. Antibodies led to thrombocytopenia within two hours and allowed the dose-dependent adjustment of the platelet count. The iDTR model caused complete thrombocytopenia within four days, which could be sustained for up to 11 days. Neither platelet depletion approach caused platelet activation. Only the iDTR model allowed efficient platelet transfusion by keeping endogenous platelet levels low and maintaining exogenous platelet levels over longer time periods, thus providing clear advantages over antibody-based methods. Transfused platelets were fully functional in vivo, and our model allowed examination of transgenic platelets. Using donor platelets from already available genetically modified mice or ex vivo treated platelets, may decrease the necessity of platelet-specific mouse strains, diminishing off-target effects and thereby reducing animal numbers. |
format | Online Article Text |
id | pubmed-7271594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Ferrata Storti Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-72715942020-06-12 Genetic platelet depletion is superior in platelet transfusion compared to current models Salzmann, Manuel Schrottmaier, Waltraud C. Kral-Pointner, Julia B. Mussbacher, Marion Volz, Julia Hoesel, Bastian Moser, Bernhard Bleichert, Sonja Morava, Susanne Nieswandt, Bernhard Schmid, Johannes A. Assinger, Alice Haematologica Articles Genetically modified mice have advanced our knowledge on platelets in hemostasis and beyond tremendously. However, mouse models harbor certain limitations, including availability of platelet specific transgenic strains, and off-target effects on other cell types. Transfusion of genetically modified platelets into thrombocytopenic mice circumvents these problems. Additionally, ex vivo treatment of platelets prior to transfusion eliminates putative side effects on other cell types. Thrombocytopenia is commonly induced by administration of anti-platelet antibodies, which opsonize platelets to cause rapid clearance. However, antibodies do not differentiate between endogenous or exogenous platelets, impeding transfusion efficacy. In contrast, genetic depletion with the inducible diphtheria toxin receptor (iDTR) system induces thrombocytopenia via megakaryocyte ablation without direct effects on circulating platelets. We compared the iDTR system with antibody-based depletion methods regarding their utility in platelet transfusion experiments, outlining advantages and disadvantages of both approaches. Antibodies led to thrombocytopenia within two hours and allowed the dose-dependent adjustment of the platelet count. The iDTR model caused complete thrombocytopenia within four days, which could be sustained for up to 11 days. Neither platelet depletion approach caused platelet activation. Only the iDTR model allowed efficient platelet transfusion by keeping endogenous platelet levels low and maintaining exogenous platelet levels over longer time periods, thus providing clear advantages over antibody-based methods. Transfused platelets were fully functional in vivo, and our model allowed examination of transgenic platelets. Using donor platelets from already available genetically modified mice or ex vivo treated platelets, may decrease the necessity of platelet-specific mouse strains, diminishing off-target effects and thereby reducing animal numbers. Ferrata Storti Foundation 2020-06 /pmc/articles/PMC7271594/ /pubmed/31537686 http://dx.doi.org/10.3324/haematol.2019.222448 Text en Copyright© 2020 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher. |
spellingShingle | Articles Salzmann, Manuel Schrottmaier, Waltraud C. Kral-Pointner, Julia B. Mussbacher, Marion Volz, Julia Hoesel, Bastian Moser, Bernhard Bleichert, Sonja Morava, Susanne Nieswandt, Bernhard Schmid, Johannes A. Assinger, Alice Genetic platelet depletion is superior in platelet transfusion compared to current models |
title | Genetic platelet depletion is superior in platelet transfusion compared to current models |
title_full | Genetic platelet depletion is superior in platelet transfusion compared to current models |
title_fullStr | Genetic platelet depletion is superior in platelet transfusion compared to current models |
title_full_unstemmed | Genetic platelet depletion is superior in platelet transfusion compared to current models |
title_short | Genetic platelet depletion is superior in platelet transfusion compared to current models |
title_sort | genetic platelet depletion is superior in platelet transfusion compared to current models |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271594/ https://www.ncbi.nlm.nih.gov/pubmed/31537686 http://dx.doi.org/10.3324/haematol.2019.222448 |
work_keys_str_mv | AT salzmannmanuel geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT schrottmaierwaltraudc geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT kralpointnerjuliab geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT mussbachermarion geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT volzjulia geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT hoeselbastian geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT moserbernhard geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT bleichertsonja geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT moravasusanne geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT nieswandtbernhard geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT schmidjohannesa geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels AT assingeralice geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels |